Determinants of Adoption for an Oncology Medicine

A Five-Layer Systems Framework for Understanding and Accelerating Adoption of an Oncology Medicine

All views expressed are my own and do not represent the views of my employer or any affiliated organization.

Photo by National Cancer Institute on Unsplash

Contents

1. Prologue: The Universal Architecture of Adoption
   Everett Rogers’ diffusion theory and why adoption speed and penetration both matter
2. The Adoption Question: What Actually Determines Drug Uptake
   Underpinning factors that drive a gap between regulatory approval and real-world prescribing
3. Framework: The Five Layers of Oncology Adoption
   (A) Layer 1: Clinical Validation — Establishing Medical Legitimacy
   (B) Layer 2: Payer Coverage — Translating Legitimacy into Access
   (C) Layer 3: Operational Feasibility — Can Sites Actually Deliver It?
   (D) Layer 4: Physician Behavior and Peer Diffusion — The Human Accelerator
   (E) Layer 5: External Shocks — When Systems Reconfigure
4. How the Layers Interact: A Systems View
   Why a single weak layer constrains overall adoption
5. Conclusion: Adoption as Strategic System Design

1. Prologue: The Universal Architecture of Adoption

Every product launch confronts the same fundamental question: how quickly and how broadly will people actually use this? The critical variables are speed and penetration: Will the innovation reach 20% market share in twelve months or thirty-six? Will it plateau at 60% or peak at 85%?

These questions have concrete implications: billions in revenue, strategic resource allocation, and — in pharmaceuticals — the reliability of supply forecasts that enable manufacturers to meet patient demand without shortages or excess inventory.

In 1962, sociologist Everett Rogers published Diffusion of Innovations, documenting a universal pattern in how new ideas spread through populations. Adopters naturally segment into five groups: innovators (2.5%), early adopters (13.5%), early majority (34%), late majority (34%), and laggards (16%). This pattern emerged from studying hundreds of innovations across domains and proved remarkably predictive. See illustration below

While the Rogers curve is universal, the forces that drive adoption are always contextual. In oncology, adoption is shaped by regulatory processes, economic gatekeepers, operational constraints, and human psychology in ways that can dramatically accelerate or suppress adoption at each stage of the curve.

2. The Adoption Equation: What Actually Determines Oncology Drug Uptake

When an oncology drug receives FDA approval, manufacturers often project rapid uptake based on clinical trial results. The implicit assumption: strong efficacy data will naturally translate into prescribing behavior. According to a 2024 survey of nearly 300 oncology stakeholders, reimbursement issues and prior authorization hurdles emerged as significant barriers to prescribing — revealing a fundamental gap between regulatory approval and real-world adoption.¹ A 2025 follow-up survey confirmed these patterns persist: administrative burden, payer restrictions, and access friction remain prominent constraints even for clinically validated therapies.

What determines the pace and ceiling of adoption? This article synthesizes publicly available research to build a framework for understanding oncology drug adoption in the United States. Adoption operates through distinct layers, each controlled by different stakeholders and mechanisms. A drug can penetrate one layer brilliantly yet stall at the next, creating adoption curves that diverge dramatically from clinical potential.

3. Framework: The Five Layers of Oncology Adoption

3A. Layer 1 | Clinical Validation

The journey from molecule to medicine begins with a question: Does the medical community believe this drug should be used? In oncology, that question is answered through clinical evidence, regulatory approval, guideline endorsement, peer-reviewed publication, and professional consensus — a process that operates less like a binary switch and more like a gradual crystallization of medical opinion.

The sub-sections below follow the approximate sequence through which clinical validation unfolds in the real world — from evidence generation through regulatory action, guideline endorsement, and pathway adoption. Each stage gates the next: weak evidence limits what the FDA will approve, which limits what guidelines endorse, which limits what pathways prefer.

3A. Part I — Trial Design, Evidence Quality, and Endpoints

Clinical validation begins with the pivotal trial — and the design of that trial shapes everything that follows. Two characteristics matter most: the phase of the trial and the endpoints it measures. These are deeply entangled, and together they determine the strength of the evidentiary package that flows into every downstream decision.

Phase 3 randomized controlled trials are the evidentiary gold standard. They provide comparative data — typically against standard of care — that guideline panels, payers, and physicians require to confidently position a new therapy. An active comparator arm enables direct assessment of relative benefit, which is what every stakeholder actually needs to make a decision. In practice, NCCN Category 1 recommendations — the strongest endorsement — almost always require well-designed Phase 3 data.

Phase 2 trials — particularly single-arm studies — can support FDA approval but introduce uncertainty that propagates through the entire system. Without a comparator arm, the magnitude of benefit relative to existing options is inferred rather than demonstrated. Guideline panels may list the therapy as an option but rarely designate it as preferred. Payers treat single-arm Phase 2 data with greater skepticism, often requiring prior authorization or imposing step therapy until Phase 3 confirmation. Physicians, especially in community settings, are less comfortable initiating therapy when the comparative evidence base is thin.

Phase 1/1b expansion cohort data occasionally support approvals in settings of high unmet need, typically based on response rates in heavily pretreated populations. These generate the most cautious downstream response: narrow guideline mentions, restrictive payer coverage, and adoption concentrated among academic oncologists comfortable interpreting early-phase data and managing unfamiliar toxicity profiles.

Within any trial phase, the endpoint hierarchy further stratifies adoption momentum.

Overall survival (OS) remains the gold standard endpoint. An OS benefit is unambiguous: patients lived longer. When a therapy demonstrates statistically significant and clinically meaningful OS improvement, it creates adoption momentum that is difficult for any downstream layer to resist. Guideline panels assign stronger recommendation categories, payers face pressure to provide coverage without restrictive management, and physicians prescribe with greater confidence. Therapies with OS data are also far more resilient to post-approval challenges — less likely to face unfavorable ICER value assessments, less vulnerable to competitive displacement, and less susceptible to formulary restrictions.

When OS data are absent — as is increasingly common with approvals based on progression-free survival (PFS), objective response rate (ORR), or duration of response (DoR) — the adoption trajectory is materially different. PFS-only data are treated by many stakeholders as provisional. Payers may impose step therapy or prior authorization requirements pending OS readouts. Guideline panels may assign weaker recommendation categories. Physicians, particularly in community settings, may defer adoption until survival data mature — a rational response given the historical record of PFS benefits that did not translate into OS gains.

The magnitude of benefit matters too. A 6-month OS improvement creates fundamentally different adoption dynamics than a 2-month improvement, particularly when weighed against toxicity, cost, and treatment burden.

Safety and tolerability interact with efficacy to shape the net clinical value proposition. A therapy demonstrating 6-month OS improvement but requiring frequent hospitalizations for cytokine release syndrome or severe neurotoxicity faces different dynamics than one with 3-month OS benefit and minimal Grade 3+ events. Oncologists evaluate therapies across efficacy endpoints, safety profile, quality of life, and healthcare resource utilization simultaneously — and payers increasingly assess value frameworks incorporating all of these dimensions.

The practical effect of these interacting factors: a therapy approved on Phase 3 OS data may reach 50% of its addressable market within 18–24 months. The same therapy approved on Phase 2 single-arm ORR data may take 30–42 months to reach the same penetration — not because the drug is less effective, but because the evidence package hasn’t earned full-system confidence. Therapies with >4-month OS gain from Phase 3 trials typically receive NCCN Category 1 recommendations within 6 months of publication, while those relying on surrogate endpoints from earlier-phase trials may remain at weaker recommendation categories for 12+ months.

3A. Part II — Conference Presentations and Publication

Before or concurrent with FDA approval, pivotal trial data enter professional consciousness through two channels: conference presentations and journal publication. Both shape the environment into which the regulatory decision arrives.

Pivotal trial data are increasingly presented at major conferences — ASCO, ESMO, ASH — typically 3–12 months before or concurrent with FDA approval. These presentations establish early awareness among key opinion leaders, generate professional discussion in advance of regulatory action, and signal forthcoming clinical change.

Strong conference presentations can accelerate post-approval adoption by pre-positioning the therapy in prescriber consciousness. Conversely, underwhelming data or safety signals at major conferences can dampen enthusiasm before approval even occurs. Late-breaking abstract slots at ASCO or ESMO signal high-impact data and generate outsized attention relative to poster presentations.

Publication venue functions as a parallel quality signal. Top-tier journals — The New England Journal of Medicine, The Lancet, JAMA — carry weight because editorial vetting by leading experts signals importance.

Physicians, particularly those outside major academic centers, use publication venue as a heuristic that influences tumor board discussions, shapes continuing medical education, and builds the professional consensus that precedes widespread use.

A pivotal trial published in NEJM enters the professional conversation differently than one published in a lower-impact specialty journal. Together, conference presentations and journal publications create a pre-approval awareness gradient. By the time the FDA acts, the medical community has already formed preliminary opinions about where the therapy fits — opinions that accelerate or constrain everything that follows.

3A. Part III — FDA Approval: The Regulatory Gate

With trial data generated and disseminated, the FDA’s decision determines whether the therapy can legally enter the market — and the nature of that decision sends a signal that reverberates through every subsequent layer.

Regular approval is granted on the basis of demonstrated clinical benefit — in practice, this almost always means Phase 3 data showing OS improvement or validated surrogate endpoints. Regular approval signals to the entire system that the evidentiary bar has been fully cleared. It accelerates formulary placement, reduces prior authorization friction, and gives physicians confidence that the therapy rests on durable evidence.

Accelerated approval permits earlier access based on surrogate endpoints reasonably likely to predict clinical benefit, with a requirement that sponsors conduct confirmatory post-marketing trials. While it opens the door, it introduces conditional uncertainty. Between 2013 and 2023, the FDA withdrew accelerated approvals for over 20 oncology indications where confirmatory trials failed to verify clinical benefit — including high-profile withdrawals for atezolizumab in triple-negative breast cancer and nivolumab in hepatocellular carcinoma. These withdrawals reinforced caution across the system: accelerated approvals increasingly face restrictive coverage policies and narrower guideline recommendations until confirmatory data mature.

Breakthrough therapy designation, while not a separate approval pathway, signals FDA’s assessment that the drug may offer substantial improvement over existing treatments. The designation functions as a credibility signal that can accelerate KOL engagement and pre-launch market preparation.

The approval pathway directly reflects the trial evidence from Part I. Phase 3 OS data typically lead to regular approval; Phase 2 surrogate endpoint data typically lead to accelerated approval. The practical consequence: regular approval accelerates full-system adoption by 6–12 months relative to accelerated approval, and accelerated approvals face 20–40% higher rates of payer utilization management until confirmatory data are available. Withdrawal risk (historically ~15–20% of oncology accelerated approvals) must be modeled in long-range forecasts.

3A. Part IV — Guideline Inclusion and Recommendation Strength

With FDA approval secured, the therapy enters the guideline evaluation process — the stage at which professional consensus formally crystallizes.

According to NCCN, its Clinical Practice Guidelines apply to more than 97% of people living with cancer in the United States.² These guidelines serve as the primary clinical validator in American oncology, signaling to physicians, payers, and hospital administrators that a therapy has crossed from experimental to standard. Though dated, a 2006 survey of 49 senior medical directors from Blue Cross Blue Shield Association found that 78% indicated NCCN guidelines should be the standard for clinical policy in centers of excellence³ — a view that has only strengthened as pathways have become more prevalent.

The pathway from approval to guideline inclusion (median: 8–12 months post-approval for strong Phase 3 data) typically runs through key opinion leaders who serve on NCCN panels. A Category 1 recommendation — based on high-level evidence and uniform NCCN consensus — carries far more adoption momentum than Category 2A (lower-level evidence or NCCN consensus with some disagreement) or Category 2B (lower-level evidence and significant disagreement). These distinctions translate directly into institutional formulary decisions, insurance coverage policies, and physician confidence.

The connection to Parts I and III is direct: Phase 3 OS data leading to regular approval are the evidence profile most likely to earn Category 1 status. Phase 2 surrogate endpoint data leading to accelerated approval typically yield Category 2A at best — and the weaker recommendation category propagates into slower formulary adoption and more restrictive payer coverage.

NCCN guidelines are comprehensive: for a given cancer type and clinical scenario, they list all evidence-supported treatment options — sometimes five, ten, or more regimens — organized by evidence category and clinical context. Their purpose is to define the boundaries of acceptable practice, not to direct physicians toward a single choice. This breadth is valuable for clinical flexibility but creates a practical challenge: when a guideline presents multiple options, which one does a physician actually select?

3A. Part V — Clinical Pathways: From Guideline Options to Preferred Regimens

This is where clinical pathways enter — and understanding the distinction between guidelines and pathways is essential for anyone forecasting adoption.

NCCN guidelines answer the question: What treatments are medically acceptable? They define the universe of evidence-supported options.

Clinical pathways answer a different question: Which treatment should you use first? Pathways take the menu of guideline-listed options and narrow them to one or two preferred regimens based on a clear hierarchy: oncologic efficacy first, then toxicity, then cost.⁴

The distinction matters enormously for adoption. A drug can be listed in NCCN guidelines as a Category 1 option — fully validated, broadly endorsed — and still see limited uptake if clinical pathways at major treatment sites designate a competing regimen as preferred. Conversely, a drug designated as the preferred pathway regimen receives structural advantages that accelerate adoption beyond what guideline listing alone would achieve.

Pathways are decision tools embedded in the clinical workflow. They are increasingly integrated into electronic health record (EHR) systems, appearing at the point of care when an oncologist opens a treatment order. Preferred regimens appear first in treatment order sets, require minimal justification, and flow through prior authorization more smoothly. Alternative regimens — still guideline-supported, still clinically appropriate — require additional documentation explaining why the preferred option wasn’t selected. This documentation burden, while not prohibitive, creates friction that meaningfully shifts prescribing patterns at scale.

Major pathway programs include Via Oncology (now part of Elsevier), McKesson’s Clear Value Plus powered by NCCN, and various health system-specific pathways. According to a 2016 Genentech survey of 202 oncologists, 53% reported using cancer treatment guidelines, 45% used clinical pathways, and 42% used both.⁵ Notably, nearly half of oncologists weren’t systematically using structured decision frameworks — even with strong clinical evidence and institutional endorsement. The pathway between clinical validation and actual prescribing runs through individual physicians, each making independent judgments about risk, benefit, and appropriateness.

To summarize the full Layer 1 sequence: FDA approval grants legal permission to market and sell the drug — without it, nothing else matters. NCCN guideline inclusion establishes the drug as a medically legitimate option within the professional community, opening the door to payer coverage and institutional formulary listing. Clinical pathway designation as preferred channels actual prescribing toward the drug over competing options that are equally guideline-supported — it converts legitimacy into default behavior. Each level narrows the funnel and increases adoption velocity, but they operate on different timescales and are controlled by different stakeholders.

Pathway inclusion as ‘preferred’ increases prescribing velocity by 40–60% vs. ‘alternative’ positioning. Pathway decisions lag guideline inclusion by 3–9 months as pathway committees evaluate comparative value, and pathway exclusion — being guideline-listed but not pathway-included — can suppress adoption by 30–50% in pathway-adherent practices.

3B. Layer 2 | Payer Coverage — Translating Clinical Validation into Access

If clinical validation determines whether a drug should be used, payer coverage determines whether it can be. Coverage doesn’t happen automatically. A JAMA Oncology research letter examining oncology coverage decisions from 2010–2019 reported a median payer coverage lag of approximately four months from FDA approval⁶ — four months during which physicians might believe in a therapy and patients might need it, but reimbursement machinery has not caught up.

Even after coverage is granted, utilization management creates friction. According to MMIT Analytics data from 2024, 56% of U.S. covered lives are affected by new-to-market blocks⁷ — bureaucratic mechanisms designed to slow or prevent use of recently approved therapies until payers assess value and negotiate pricing.

3B. Part I — Reimbursement Mechanics and Utilization Management

Between FDA approval and a physician’s ability to actually prescribe with confidence of payment, three friction points arise in sequence.

The first is billing infrastructure. For injectable and infusible oncology drugs covered under Medicare Part B, reimbursement hinges on assignment of a J-code — a Healthcare Common Procedure Coding System (HCPCS) code identifying the drug for billing. Manufacturers must apply to CMS for a permanent J-code after approval, a process typically taking 1–2 quarters. During this interim period, drugs are billed under miscellaneous J-codes (e.g., J9999), introducing reimbursement uncertainty that suppresses early adoption — particularly in community practices with limited capacity to navigate billing complexity. Manufacturers often work with specialty pharmacies and buy-and-bill support programs to bridge this gap. Once a permanent J-code is assigned, CMS establishes the Average Sales Price (ASP) plus a percentage add-on (typically 6%) as the reimbursement rate, creating predictable economics that reduce friction.

The second is prior authorization. Even after a drug is covered, payers require physicians to demonstrate medical necessity before approving payment — a process involving forms, clinical documentation, approvals, and appeals that can take days or weeks. More than one-third of oncologists said authorizations have frequently hampered prescribing, and more than half said they have frequently or occasionally avoided prescribing new drugs because of this barrier.¹

The third is value assessment. As oncology therapies have grown increasingly expensive — particularly novel modalities like CAR-T, bispecifics, and antibody-drug conjugates — payers have adopted value frameworks from ICER, ASCO, and NCCN⁸ to systematically assess clinical benefit relative to cost. These frameworks influence formulary placement, prior authorization criteria, and negotiated pricing. A therapy deemed ‘high value’ by multiple frameworks may secure favorable coverage; one flagged as incrementally beneficial at substantially higher cost faces restrictive utilization management.

These three mechanisms — billing gaps, authorization barriers, and value-based gatekeeping — operate in parallel and compound each other. A new therapy without a permanent J-code, requiring prior authorization, and facing an unfavorable ICER assessment can be functionally inaccessible for months after FDA approval despite clear clinical validation.

3B. Part II — Medical Benefit vs. Pharmacy Benefit

Benefit design — whether a drug is covered under medical versus pharmacy benefit — fundamentally shapes access mechanics. Medical benefit drugs (infused or injected in clinical settings) follow one set of economic rules, with reimbursement tied to acquisition cost plus administration fees. Pharmacy benefit drugs (oral or self-administered) follow entirely different rules, subject to formulary tiers, step edits, and patient cost-sharing that can run into thousands of dollars per month.⁹

Patient cost-sharing directly affects adherence and access. Research consistently shows that lower out-of-pocket costs correlate with higher medication adherence, while higher coinsurance rates — particularly for specialty tiers — correlate with prescription abandonment and treatment discontinuation.⁵

3B. Part III — Biosimilar Economics: When Layer 2 Overrides Clinical Equivalence

The biosimilar market illustrates how Layer 2 economics can override clinical equivalence. Biosimilars saved payers $7.0 billion in 2023 alone, amounting to $19.2 billion since 2017¹⁰ — yet uptake varies dramatically by molecule based on rebate structures. When significant rebates associated with a reference product account for a large share of specialty drug rebates, pharmacy benefit managers find little economic incentive to push biosimilar substitution — regardless of price advantage. This dynamic is explored further in Section 4.

Get Saad Ahmad’s stories in your inbox

Join Medium for free to get updates from this writer.

Remember me for faster sign in

The four-month median coverage lag, J-code assignment timelines (1–2 quarters post-approval), and utilization management barriers collectively suppress uptake for 12–18 months post-coverage, particularly for high-cost therapies. Medical benefit drugs achieve 30–50% faster uptake than pharmacy benefit equivalents due to lower patient cost-sharing friction.

3C. Layer 3 | Operational Feasibility — Can Sites Actually Deliver It?

Even when clinical validation is secure and coverage is in place, a third question remains: Can treatment centers physically deliver the therapy? For conventional oral or standard infusion therapies, existing infrastructure usually works — the drug enters established dispensing and administration workflows with minimal friction. But for therapies requiring specialized facilities, trained personnel, new monitoring protocols, or complex logistics, operational feasibility becomes the binding constraint on adoption regardless of clinical merit or payer coverage.

Operational complexity exists on a spectrum. At the lower end, a new oral targeted therapy with a REMS program requiring liver function monitoring every two weeks adds modest burden — but enough to slow adoption in smaller practices without dedicated nurse coordinators. A new infusion therapy requiring a four-hour administration window and two-hour post-infusion observation strains sites that schedule thirty-minute infusions back-to-back. A therapy requiring a companion diagnostic before prescribing adds a step that delays treatment initiation and creates friction for physicians accustomed to empiric treatment decisions. These are not exotic examples — they represent routine operational considerations that create measurable adoption drag across thousands of community oncology practices.

At the extreme end of the spectrum sits CAR-T therapy, which illustrates what happens when operational complexity becomes the dominant constraint. Unlike drugs dispensed from pharmacies or mixed in hospital pharmacies, CAR-T requires extracting a patient’s T-cells through apheresis, shipping them to a specialized manufacturing facility, genetically modifying them, expanding the cell population, and shipping them back — a process taking 2–4 weeks and vulnerable to manufacturing failures.¹² Approximately 150–200 certified CAR-T centers exist in the U.S. as of 2024, concentrated in major academic medical centers with intensive care capacity to manage severe side effects like cytokine release syndrome. International data shows similar constraints: only 17–38% of eligible patients receive CAR-T within one month of referral, with limited hospital capacity identified as the leading barrier.¹⁴

CAR-T reimbursement further illustrates the challenge. CMS assigns CAR-T cases to DRG 018, with a base payment increasing to $314,176 in fiscal year 2026.¹³ Even at this level, the base payment often falls short of covering full treatment costs when complications arise — discouraging institutions from establishing or expanding programs. A therapy can have unambiguous clinical validation, full payer coverage, and enthusiastic physician support, yet remain inaccessible to most patients because the infrastructure to deliver it simply doesn’t exist at scale.

3C. Part I — Manufacturing Reliability and Supply Assurance

Beyond site-level infrastructure, supply chain reliability shapes institutional willingness to adopt. Large pharmaceutical companies with diversified manufacturing networks, robust quality systems, and track records of supply continuity offer reassurance that smaller biotech firms cannot always match. When a therapy comes from a manufacturer with proven supply chain resilience — multiple production sites, validated processes, inventory buffers — payers are more confident granting unrestricted formulary access, and providers are more willing to commit to the therapy as a standard option.

Conversely, supply uncertainty from single-site manufacturers introduces caution. Payers may impose step edits or prior authorizations until supply stability is demonstrated. Providers may defer adoption until confident the therapy will be consistently available. This is particularly salient for therapies requiring continuous dosing or long treatment durations — oncologists are reluctant to initiate patients on regimens that might be interrupted by supply failures.

3C. Part II — Practice Type and Geographic Constraints

Research analyzing Medicare claims for immunotherapies shows substantial variation in adoption rates across practice categories, with rural and smaller practices adopting novel agents more slowly than large academic centers.⁷ These patterns reflect not just knowledge gaps but operational realities: smaller practices may lack infusion suites, specialized staffing, patient volume to justify new equipment investments, or proximity to the laboratory and diagnostic infrastructure that complex therapies require.

For any therapy with operational requirements beyond standard dispensing or infusion, the question is not just “how many sites can deliver this today?” but “how quickly can that number grow?” A therapy deliverable at 3,000 community oncology practices has a fundamentally different adoption ceiling than one limited to 150 certified centers — and geographic concentration creates access barriers that no amount of clinical validation can overcome.

3D. Layer 4 | Physician Behavior and Peer Diffusion — The Human Accelerator

Beyond validation, coverage, and infrastructure lies the most human layer: the physician’s decision to actually prescribe. This layer operates through mechanisms that are simultaneously rational and social, evidence-based and emotional, individual and collective.

3D. Part I — Knowledge Gaps and Treatment Inertia

Knowledge gaps persist even for well-validated therapies, especially in community settings. A 2024 IQVIA Institute analysis covering seven countries found that approximately 70% of referring physicians stated they would benefit from more information about CAR-T cell therapy. In one U.S. study, physician preference for conventional treatments was the primary barrier to CAR-T cell therapy for 32% of patients treated in community practices¹⁵ — not insurance denials, not operational constraints, but physician comfort with familiar regimens.

Treatment inertia is powerful. Oncologists develop patterns over years of training and experience, patterns reinforced by outcomes, teaching from mentors, departmental cultures, and accumulated weight of thousands of prior decisions. Changing those patterns requires not just new evidence but new habits, and habit formation in medicine is slow.

3D. Part II — Commercial Engagement and Medical Education

This gap is rarely closed by publications or guidelines alone. It is bridged through professional networks and structured education. Commercial engagement plays a role: sales representatives influence prioritization and awareness, while medical science liaisons (MSLs) provide scientific exchange, helping clinicians understand mechanism, data interpretation, patient selection, and clinical management.

Key opinion leaders (KOLs) function as social validators. Early adoption by respected clinicians, followed by peer dissemination at conferences and through professional networks, accelerates diffusion in ways direct marketing cannot replicate. When a well-regarded oncologist at a major cancer center publishes real-world experience, presents findings at ASCO or ESMO, or discusses results at regional tumor boards, it carries weight that transforms tentative interest into confident adoption.

3D. Part III — EHR Integration and Point-of-Care Defaults

The clinical pathways described in Layer 1 exert their strongest influence when embedded directly in EHR systems at the point of care. When the preferred regimen appears as the default in a treatment order set — requiring a single click to select and no documentation to justify — the cognitive burden of adopting new evidence drops dramatically. The pathway becomes the default, and defaults shape behavior.

This matters because physician adoption is not purely a knowledge problem. Even clinicians who are aware of new data and intellectually persuaded by it may not change behavior if the practical steps are effortful. EHR-embedded pathways remove that effort, converting intellectual agreement into prescribing action. Community practice adoption typically lags academic centers by 12–24 months (median: ~16 months) for therapies requiring new treatment paradigms, and EHR pathway integration can compress this gap by 6–12 months.

3E. Layer 5 | External Shocks — When Systems Reconfigure

The first four layers describe steady-state forces shaping adoption under routine circumstances. The fifth layer represents everything that can break those conditions: supply disruptions, manufacturing failures, natural disasters, pandemics, regulatory crises. These discontinuities can temporarily override all other determinants — and sometimes the changes they force turn out to be permanent.

3E. Part I — The Platinum Chemotherapy Shortage

Consider the platinum chemotherapy shortage beginning in early 2023. Carboplatin has been in shortage since April 2023. Cisplatin experienced a prolonged shortage from February 2023 until June 2024.¹⁶ These aren’t niche drugs — they’re backbone agents for multiple cancer types, including lung, ovarian, bladder, and head and neck cancers.

During the shortage period, cisplatin use for head and neck cancer decreased by 15% compared with pre-shortage levels. The lowest use occurred in June and July 2023, with a 60% decrease.¹⁷ Physicians didn’t suddenly decide cisplatin was ineffective; it simply wasn’t available.

From May to August 2023, cisplatin use decreased by 15%, accompanied by increases in carboplatin by 40%, paclitaxel by 24%, cetuximab by 15%, and fluorouracil by 5%.¹⁸ Alternative use of cetuximab resulted in a 16% total cost increase, leading to a 144-fold increase in costs at the administrative level.¹⁹

3E. Part II — Persistent Treatment Pattern Changes

Of patients already receiving cisplatin before the shortage, 10% were shifted to a different drug during the shortage due to complete lack of availability. **All patients who started cetuximab during the shortage continued to receive the more expensive drug even when the cisplatin shortage ended.**²⁰

Once switched, patients stayed switched — either because re-switching seemed unnecessarily disruptive, the alternative was working well enough, or institutional formularies and order sets had been updated and reverting required effort and justification.

A survey conducted by NCCN showed that 93% of cancer centers reported a shortage of carboplatin and 70% reported shortages of cisplatin, yet 100% said they were still able to treat patients who needed cisplatin without delays or claim denials²¹ — demonstrating system resilience through rationing and substitution strategies. But that resilience came at the cost of treatment pattern disruption and increased expenditure.

Supply shocks create permanent shifts that override all other layers. Once physicians adopt an alternative during a shortage, 60–80% continue that alternative indefinitely. Competitor products benefiting from shortages can capture 10–30% incremental market share persisting years beyond the supply disruption, and manufacturers dependent on single-source or geographically concentrated manufacturing face asymmetric risk — a six-month shortage can create multi-year market share losses.

4. How the Layers Interact: A Systems View

The layers aren’t independent — they amplify or dampen each other in complex ways. Understanding adoption requires seeing the system as interlinked constraints rather than linear steps. Three interaction patterns recur.

Bottleneck dominance. A single weak layer can constrain overall adoption regardless of strength in other layers. CAR-T therapy demonstrates this clearly: strong clinical validation and stable supply conditions cannot overcome a therapy that only ~150 sites can deliver and that most referring physicians don’t fully understand. The binding constraint is Layers 3 and 4, and no amount of investment in Layer 1 or Layer 2 will move the curve until those bottlenecks are addressed.

Layer override. In some cases, one layer’s dynamics are powerful enough to override what the other layers would predict. Biosimilar adoption illustrates this: oncology biosimilars and adalimumab biosimilars have nearly identical profiles across Layers 1, 3, 4, and 5 — equivalent clinical evidence, no operational barriers, growing physician comfort, no supply disruptions. Yet oncology biosimilars have reached 76–90% market share while adalimumab biosimilars stall at roughly 22%.²²,²³ The difference is entirely Layer 2 rebate economics, which override every other favorable condition.

Cascading acceleration. When layers align favorably, they don’t just add — they multiply. A therapy with Phase 3 OS data (Layer 1) leading to regular approval and rapid NCCN Category 1 endorsement faces less payer friction (Layer 2), which accelerates formulary placement, which enables pathway inclusion as preferred (still Layer 1), which embeds in EHR order sets (Layer 4), which drives community practice adoption — each step reducing friction for the next. The adoption curve steepens not because any single layer is unusually strong, but because no layer is creating drag.

The strategic implication is that diagnosing the binding constraint matters more than optimizing any individual layer. The question is never “how strong is our clinical data?” or “how favorable is our payer coverage?” in isolation. It is always “which layer is currently governing our adoption rate, and what would it take to release that constraint?”

5. Conclusion: Adoption as Strategic System Design

Oncology drug adoption isn’t a single decision or linear process — it’s an emergent property of multiple interconnected systems, each operating according to its own logic, each controlled by different stakeholders with different incentives.

Clinical validation opens the possibility that a drug might be used. Payer coverage determines whether patients can financially access it. Operational feasibility determines how many sites can deliver it. Physician behavior determines who prescribes it. External shocks can temporarily override all other layers, forcing new paths that often persist long after the disruption resolves.

Global spending on cancer medication was estimated at $223 billion in 2023 and is on track to reach $409 billion by 202⁸²⁴, growth driven by scientific innovation, aging populations, and expanding indications. With this growth comes intensifying access pressures. Over the next five years, 88 biologics face loss of exclusivity, representing an estimated market of $100 billion or more²⁵ — a patent cliff that will test whether biosimilar adoption can generate needed savings while maintaining patient access to cutting-edge treatments.

For commercial leaders, the imperative is to identify the binding layer at each stage of launch, sequence interventions deliberately across layers, and anticipate supply disruptions that can permanently reshape competitive dynamics. Understanding which layer controls adoption at which stage, and how layers interact to amplify or dampen each other, is essential for realistic forecasting, strategic planning, and ultimately, ensuring patient access to innovative therapies.

The drugs that succeed aren’t always the most clinically innovative or scientifically elegant. They’re the ones that successfully penetrate all five layers, navigating regulatory validation, payer economics, operational constraints, physician behavior, and supply chain reliability with equal skill.

Adoption is not governed solely by clinical evidence or market demand. It is governed by the system through which the therapy must travel — and systems move only as fast as their slowest layer.

References

1. Oncology News Central. 2024 Drug Survey results. https://www.oncnewscentral.com/drug-survey-2024
2. National Comprehensive Cancer Network. Development and Update of Guidelines. https://www.nccn.org/guidelines/guidelines-process/development-and-update-of-guidelines
3. Blue Cross Blue Shield Association. Survey of medical directors on NCCN guidelines as standard for clinical policy. 2006.
4. Via Oncology. Clinical pathway development methodology prioritizing oncologic efficacy, toxicity, and cost. 2024.
5. Genentech. Survey of oncologists and managed care organizations on guideline and pathway usage. 2016.
6. JAMA Oncology. Research letter on payer coverage lag from FDA approval. Study period 2010–2019.
7. MMIT Analytics. U.S. Market Access Insights: Policy and Restriction Data on New-to-Market Blocks. 2024.
8. ICER, ASCO, NCCN. Value assessment frameworks for oncology therapies. Multiple publications 2020–2024.
9. Pharmacy benefit coverage and patient cost-sharing analysis. Multiple payer data sources 2023–2024.
10. Association for Accessible Medicines (AAM). 2024 Biosimilars Report: Competition, Savings, and Market Access. https://accessiblemeds.org/resources/publications/2024-biosimilars-report
11. Biosimilars Council. Analysis of adalimumab biosimilar rebate structures and market impact. 2023–2024.
12. CAR-T manufacturing and logistics analysis. FDA and manufacturer data. 2023–2024.
13. Centers for Medicare & Medicaid Services. Medicare Program; FY 2026 Inpatient Prospective Payment Systems (IPPS) Final Rule. Federal Register. August 2025. DRG 018 base payment rate: $314,176.
14. IQVIA Institute for Human Data Science. Global CAR-T Cell Therapy Access and Utilization Report. 2024.
15. IQVIA Institute for Human Data Science. Global Oncology Trends 2024: Outlook to 2028. May 2024.
16. U.S. Food and Drug Administration. Drug Shortages: Current and Resolved Drug Shortages and Discontinuations Reported to FDA. https://www.accessdata.fda.gov/scripts/drugshortages/
17. Indurlal P, et al. Impact of cisplatin and carboplatin drug shortage on treatment patterns and costs for head and neck cancer. Abstract 1. ASCO Quality Care Symposium; September 27–28, 2024; San Francisco.
18. Garey JS, et al. Analysis of chemotherapy utilization patterns during the 2023 platinum shortage. McKesson Specialty Health Analytics. 2024.
19. Indurlal P, et al. Impact of cisplatin and carboplatin drug shortage on treatment patterns and costs for head and neck cancer. Abstract 1. ASCO Quality Care Symposium; September 27–28, 2024; San Francisco.
20. Indurlal P, et al. Impact of cisplatin and carboplatin drug shortage on treatment patterns and costs for head and neck cancer. Abstract 1. ASCO Quality Care Symposium; September 27–28, 2024; San Francisco.
21. National Comprehensive Cancer Network Best Practices Committee. Survey on platinum chemotherapy shortages. Conducted May 23–31, 2023. Results reported June 2023.
22. Samsung Bioepis. Biosimilar Market Report Q4 2024. https://www.samsungbioepis.com/upload/attach/SB+Biosimilar+Market+Report+Q4+2024.pdf
23. Samsung Bioepis. Biosimilar Market Report Q3 2024. https://www.samsungbioepis.com/upload/attach/SB+Biosimilar+Market+Report+Q3+2024.pdf
24. IQVIA Institute for Human Data Science. Global Oncology Trends 2024: Outlook to 2028. May 2024.
25. IQVIA Institute for Human Data Science. Biosimilars in the United States 2023–2027: Competition, Savings, and Sustainability. September 2023.